Curis (NASDAQ:CRIS) Announces Quarterly Earnings Results

Curis (NASDAQ:CRIS) issued its quarterly earnings results on Thursday. The biotechnology company reported ($1.94) earnings per share for the quarter, topping the consensus estimate of ($2.01) by $0.07, Zacks reports.

Here are the key takeaways from Curis’ conference call:

• Updated PCNSL data showed responses in 6 of 7 BTK-inhibitor-naive patients (86%) and 10 of 39 patients (26%) whose disease had progressed on a BTK inhibitor. Curis said the results support the potential for accelerated-approval submissions, though the cohorts remain small.
• Curis had enrolled 12 patients at 11 sites in its CLL proof-of-concept study and expects to report initial data by year-end. The company hopes the combination will deepen responses, but the first update may include patients with varying amounts of treatment follow-up.
• Enrollment in the PCNSL registrational study has been “choppy” because the disease is ultra-rare; Curis expects full enrollment by the end of 2027 and said an accelerated-approval filing could follow in 2028.
• Curis reported a $40.9 million net loss for the first nine months of 2026, versus $26.9 million in the prior-year period, and had $5 million in cash at quarter-end. The company said October financing, together with existing cash, should fund operations into 2027.

Curis Stock Performance

Shares of Curis stock opened at $0.57 on Friday. The company has a fifty day simple moving average of $0.78 and a 200-day simple moving average of $8.30. Curis has a 12-month low of $0.33 and a 12-month high of $28.40.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on CRIS shares. Zacks Research upgraded shares of Curis from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 9th. HC Wainwright reaffirmed a “buy” rating on shares of Curis in a research report on Monday, August 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a report on Thursday, October 15th. Finally, Wall Street Zen upgraded Curis from a “strong sell” rating to a “hold” rating in a report on Saturday, August 22nd. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $43.00.

Curis Company Profile

Curis, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics for the treatment of cancer. The company’s research and development activities center on targeted therapies designed to address biological pathways involved in tumor growth and immune regulation. Curis’ lead investigational product is emavusertib, an oral inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). The company has evaluated emavusertib in clinical studies for hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndromes and certain forms of non-Hodgkin lymphoma.